Floatz logo

Rimiducid

Inborn Error Of Immunity

Bellicum PharmaceuticalsSmall moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Inborn Error Of Immunity cohort.

Asset / SponsorPhaseRating
Treosulfan
medac GmbH
Phase 2B
Busulfanum
medac GmbH
Phase 2B
Fludarabine
Paul Szabolcs
Phase 2B
Clofarabine
University of California, San Francisco
Phase 2CCC
Melphalan
Paul Szabolcs
Phase 2CCC

View all 15 →

Same molecule, other indications

Rimiducid is also rated in:

myelodysplastic syndromeActive
CCC
Indicative · Phase 2/3
51 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative · Phase 1/2
50 / 100
View asset →
large B-cell lymphomaActive
CCC
Indicative · Phase 2
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →